Aytu BioScience (NASDAQ:AYTU) is up 5% premarket on robust volume in reaction to its announcement that
it has sold/allocated 100K COVID-19 antibody blood tests in the U.S.
and is expecting delivery of another 500K. It has boosted the size of
its third order to 1M.
https://seekingalpha.com/news/3560809-aytu-bioscience-up-5-premarket-on-covidminus-19-test-sales
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.